Cloned (Comment) | Organism |
---|---|
recombinant expression of wild-type and mutant isoQC in isoQC-deficient HEK-293T cells | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
E225G | site-directed mutagenesis, the mutant shows reduced enzymatic activity compared to wild-type | Homo sapiens |
additional information | knockout of isoQC dramatically reduces the binding of SIRPalpha to cell surface | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
PQ529 | can efficiently inhibit the activity of both glutaminyl cyclase isozymes QC and isoQC. Treatment with PQ529 for 48 h significantly blocks the binding of CC2C6 to the cell surface in a dosage-dependent manner in wild-type, but not in isoQC-deficient cells | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cell surface | - |
Homo sapiens | 9986 | - |
Golgi apparatus | - |
Homo sapiens | 5794 | - |
Golgi membrane | unlike QC, the secreted isozyme, isozyme isoQC exclusively localizes within the Golgi complex via a transmembrane domain | Homo sapiens | 139 | - |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-glutaminyl-CD47 | Homo sapiens | - |
5-oxoprolyl-CD47 + NH3 | - |
? | |
L-glutaminyl-peptide | Homo sapiens | - |
5-oxoprolyl-peptide + NH3 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q9NXS2 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
ARP-1 cell | - |
Homo sapiens | - |
carcinoma cell | - |
Homo sapiens | - |
DLD-1 cell | - |
Homo sapiens | - |
HCT-116 cell | - |
Homo sapiens | - |
JURKAT cell | - |
Homo sapiens | - |
additional information | no activity in HEK-293T cells | Homo sapiens | - |
NCI-H929 cell | - |
Homo sapiens | - |
NU-DUL-1 cell | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-glutaminyl-CD47 | - |
Homo sapiens | 5-oxoprolyl-CD47 + NH3 | - |
? | |
L-glutaminyl-peptide | - |
Homo sapiens | 5-oxoprolyl-peptide + NH3 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
glutaminyl cyclase | - |
Homo sapiens |
glutaminyl-peptide cyclotransferase-like protein | - |
Homo sapiens |
Golgi-resident enzyme | - |
Homo sapiens |
isoQC | - |
Homo sapiens |
QPCTL | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
evolution | glutaminyl cyclase (QC, glutaminyl-peptide cyclotransferase (QPCT)) and its isoenzyme isoQC (QPCTL) belong to a family of enzymes which catalyze the formation of pyroglutamate (pGlu, pE) at N-terminus of proteins by converting glutamate/glutamine to pGlu residue | Homo sapiens |
malfunction | knockout of isoQC dramatically reduces the binding of SIRPalpha to cell surface | Homo sapiens |
metabolism | transmembrane protein CD47 is highly expressed on many types of cancer cells and can directly bind to the receptor signal regulatory protein alpha (SIRPalpha), which is highly expressed on phagocytic cells. Binding of CD47 to SIRPalpha can protect cancer cells from phagocytosis by phagocytic cells and therefore functions as the major 'don't eat me' signal. Therapeutic blockade of CD47-SIRPalpha axis can efficiently promote the macrophage-mediated phagocytosis and elimination of cancer cells. Glutaminyl cyclase isoenzyme isoQC is a regulator of SIRPalpha-CD47 axis | Homo sapiens |
physiological function | glutaminyl cyclase isoenzyme isoQC is an essential regulator of CD47-SIRPalpha axis and required for efficient phagocytic cells-mediated clearance of cancer cells. N-terminal pGlu modification of proteins may protect protein from degradation by proteases or promote protein aggregation | Homo sapiens |